Advertisement

ShockWave Medical, Inc. SWAV

Set alert

Price alert · SWAV

All alert types
334.75 0.00 0.00%

At close · May 30

334.75 Day range 334.90

52-week range unavailable

Open
334.85
Prev close
334.75
Mkt cap
12.57B
Vol
3.95M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
334.75
High
334.90
Forward P/E
55.70
Beta
0.88
Short ratio
2.24
Inst. own
98.73%
Dividend
0.00
Ex-div date
Earnings
May 6, 2024
50-d avg
326.86
200-d avg
241.38
1y target
324.27

2Y chart

Chart tools
Interval

Events in this range
  • Feb 16, 2023Earnings: —; estimate 0.99; surprise —%
  • May 8, 2023Earnings: —; estimate 0.81; surprise —%
  • Aug 7, 2023Earnings: —; estimate 0.87; surprise —%
  • Aug 7, 2023Rating: Wells Fargo · Equal-Weight → Equal-Weight
  • Aug 7, 2023Rating: Needham · Buy → Buy
  • Aug 9, 2023Rating: Morgan Stanley · Overweight → Overweight
  • Sep 28, 2023Rating: UBS · — → Neutral
  • Nov 6, 2023Earnings: —; estimate 0.81; surprise —%
  • Feb 15, 2024Earnings: —; estimate 0.92; surprise —%
  • May 6, 2024Earnings: —; estimate 1.04; surprise —%
Signals (77)
NameDateAgo
RSI: OverboughtMay 22, 20242 years ago
MACD: Sell SignalApr 12, 20242 years ago
RSI: OverboughtMar 25, 20242 years ago
RSI: OverboughtMar 19, 20242 years ago
MACD: Buy SignalMar 18, 20242 years ago
MACD: Sell SignalMar 4, 20242 years ago
MACD: Buy SignalFeb 16, 20242 years ago
RSI: OverboughtFeb 16, 20242 years ago
MACD: Sell SignalFeb 9, 20242 years ago
SMA: BullishFeb 6, 20242 years ago
SMA: BearishFeb 5, 20242 years ago
SMA: BullishFeb 1, 20242 years ago
RSI: OverboughtFeb 1, 20242 years ago
RSI: OverboughtJan 24, 20242 years ago
RSI: OverboughtJan 18, 20242 years ago
RSI: OverboughtJan 10, 20242 years ago
SMA: BullishDec 18, 20232 years ago
SMA: BearishDec 15, 20232 years ago
SMA: BullishDec 14, 20232 years ago
MACD: Buy SignalNov 29, 20232 years ago
MACD: Sell SignalNov 28, 20232 years ago
MACD: Buy SignalNov 24, 20232 years ago
RSI: OversoldNov 9, 20232 years ago
SMA: BearishNov 7, 20232 years ago
MACD: Sell SignalNov 7, 20232 years ago
SMA: BullishNov 1, 20233 years ago
SMA: BearishOct 26, 20233 years ago
SMA: BullishOct 24, 20233 years ago
MACD: Buy SignalOct 5, 20233 years ago
RSI: OversoldSep 22, 20233 years ago
MACD: Sell SignalSep 20, 20233 years ago
MACD: Buy SignalAug 28, 20233 years ago
RSI: OversoldAug 24, 20233 years ago
RSI: OversoldAug 21, 20233 years ago
RSI: OversoldAug 16, 20233 years ago
SMA: BearishAug 8, 20233 years ago
RSI: OversoldAug 7, 20233 years ago
RSI: OversoldJul 7, 20233 years ago
SMA: BearishJun 30, 20233 years ago
MACD: Sell SignalJun 23, 20233 years ago
MACD: Buy SignalJun 14, 20233 years ago
RSI: OverboughtMay 11, 20233 years ago
MACD: Sell SignalMay 3, 20233 years ago
SMA: BullishApr 11, 20233 years ago
RSI: OverboughtApr 11, 20233 years ago
RSI: OverboughtApr 5, 20233 years ago
SMA: BullishMar 14, 20233 years ago
MACD: Buy SignalMar 14, 20233 years ago
MACD: Sell SignalMar 13, 20233 years ago
SMA: BearishMar 9, 20233 years ago
SMA: BullishMar 7, 20233 years ago
SMA: BearishFeb 21, 20233 years ago
SMA: BullishFeb 17, 20233 years ago
MACD: Buy SignalJan 25, 20233 years ago
MACD: Sell SignalJan 18, 20233 years ago
RSI: OversoldJan 18, 20233 years ago
MACD: Buy SignalJan 5, 20233 years ago
MACD: Sell SignalJan 3, 20233 years ago
RSI: OversoldJan 3, 20233 years ago
MACD: Buy SignalDec 29, 20223 years ago
RSI: OversoldDec 16, 20223 years ago
MACD: Sell SignalDec 5, 20223 years ago
MACD: Buy SignalNov 25, 20223 years ago
MACD: Sell SignalNov 4, 20223 years ago
SMA: BearishNov 3, 20223 years ago
SMA: BullishOct 28, 20224 years ago
SMA: BearishOct 27, 20224 years ago
SMA: BullishOct 25, 20224 years ago
MACD: Buy SignalOct 21, 20224 years ago
SMA: BearishOct 7, 20224 years ago
MACD: Sell SignalOct 7, 20224 years ago
MACD: Buy SignalOct 5, 20224 years ago
SMA: BullishSep 28, 20224 years ago
SMA: BearishSep 22, 20224 years ago
MACD: Sell SignalAug 30, 20224 years ago
RSI: OverboughtAug 9, 20224 years ago
MACD: Buy SignalAug 3, 20224 years ago

Key statistics

Market cap
12.57B
Enterprise value
12.32B
Trailing P/E
78.76
Forward P/E
55.70
PEG ratio
2.63
Price / sales
15.95
Price / book
16.70
EPS (TTM)
4.25
Beta
0.88
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
20.75%
Revenue (TTM)
787.97M
Revenue growth
35.80%
Free cash flow
118.03M
Total cash
1.03B
Total debt
776.80M
Return on equity
24.73%
Shares outstanding
37.54M
Short % of float
5.50%
50-day average
326.86
200-day average
241.38

Analyst view

Consensus: hold

Hold
Price target (mean) 324.27 -3.1% downside
Target (low)
250.00
Target (mean)
324.27
Target (high)
348.42

Next earnings

May 6, 2024

Expected May 6, 2024. Consensus EPS estimate 1.18.

Earnings history

Financials — quick view

All financials
SWAV Revenue — quarterly 218.81M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
SWAV Net income — quarterly 55.35M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
SWAV EPS — quarterly 1.48
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024

Earnings

SWAV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 6, 2024Mar 1, 20241.04———
Feb 15, 2024Dec 1, 20230.92———
Nov 6, 2023Sep 1, 20230.81———
Aug 7, 2023Jun 1, 20230.87———
May 8, 2023Mar 1, 20230.81———
Feb 16, 2023Dec 1, 20220.99———

Upgrades / downgrades

SWAV analyst upgrades and downgrades
DateFirmActionFromTo
Oct 15, 2023Leerink Partnersinit—Outperform
Sep 28, 2023UBSinit—Neutral
Aug 9, 2023Morgan StanleymainOverweightOverweight
Aug 7, 2023Wells FargomainEqual-WeightEqual-Weight
Aug 7, 2023NeedhammainBuyBuy
Jul 9, 2023Morgan StanleyupEqual-WeightOverweight

About ShockWave Medical, Inc.

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on SWAV — it syncs with the Stock Master app.

Insider holders

SWAV insider holders
InsiderRelationLatest transactionDateShares held
FRANCIS LAURA A.DirectorStock GiftMar 25, 20244,784
GAETA RENEEChief Financial OfficerStock Award(Grant)Feb 4, 202419,890
GODSHALL DOUGLAS EVANChief Executive OfficerSaleFeb 14, 2024162,762
MOLL FREDERIC HDirectorSaleFeb 20, 2024287,521
PAPIERNIK ANTOINEDirectorConversion of Exercise of derivative securityJul 4, 202334,913
PHUNG TRINH TUOfficerStock GiftMay 21, 202450,387

Institution ownership

SWAV institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.89%3,636,4441.04BJun 29, 2023
Vanguard Group Inc9.80%3,603,0141.03BJun 29, 2023
FMR, LLC6.63%2,434,974694.97MJun 29, 2023
Wellington Management Group, LLP3.68%1,352,723386.08MJun 29, 2023
Artisan Partners Limited Partnership3.12%1,147,784327.59MJun 29, 2023
Price (T.Rowe) Associates Inc2.97%1,091,050311.40MJun 29, 2023

Fund ownership

SWAV fund ownership
Holder% heldSharesValueReported
iShares Core S&P Midcap ETF3.13%1,149,365228.84MSep 29, 2023
Vanguard Total Stock Market Index Fund3.12%1,145,905327.05MJun 29, 2023
Vanguard Small-Cap Index Fund2.57%945,622269.89MJun 29, 2023
Smallcap World Fund1.59%585,000166.96MJun 29, 2023
Vanguard Small-Cap Growth Index Fund1.47%540,949154.39MJun 29, 2023
Price (T.Rowe) Health Sciences Fund1.42%520,729148.62MJun 29, 2023
Advertisement